Reported 3 days ago
A recent analysis reveals that U.S. government health plans, particularly Medicaid, provide majority coverage for Novo Nordisk's Wegovy and Eli Lilly's Zepbound weight-loss medications, reaching over 52 million Americans. This contrasts sharply with commercial health plans, which cover less than half that amount. The high price and ongoing demand for these drugs highlight significant disparities in coverage, sparking discussions on broader insurance policies and the treatment of obesity in the U.S.
Source: YAHOO